Eribulin across multiple lines of chemotherapy: a retrospective study on quality of life and efficacy in metastatic breast cancer patients

Erica Quaquarini, Federico Sottotetti, Daniela D'Ambrosio, Alberto Malovini, Stefania Morganti, Arianna Marinello, Lorenzo Pavesi, Mara Frascaroli

Research output: Contribution to journalArticle

Abstract

This study evaluates efficacy, tolerability and health-related quality of life of eribulin in patients with metastatic breast cancer. Predictive and/or prognostic factors of outcome were also analyzed. Among 44 women receiving eribulin mesylate, one patient had a complete response, 22.7% a partial response and 25% a stable disease. Median overall survival and median progression-free survival were 11.8 and 4.5 months, respectively. Treatment was well tolerated; the most frequent adverse events were neutropenia (52%), leukopenia (50%), fatigue (38%) and alopecia (40%). No significant reductions of health-related quality of life parameters were observed. Disease control during previous chemotherapy lines was related with better outcome with eribulin. In conclusion, eribulin treatment should be considered in a multiple chemotherapy lines strategy in metastatic breast cancer.

Original languageEnglish
Pages (from-to)11-23
Number of pages13
JournalFuture Oncology
Volume13
Issue number11s
DOIs
Publication statusPublished - Apr 2017

    Fingerprint

Keywords

  • Journal Article

Cite this